Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difenamizole SCHEMBL25873 | 0.87 | GRM5 (0.62) | GRM5MAPTLMNAALDH1A1TP53 | |
| Difenamizole SCHEMBL1651121 | 0.85 | GRM5 (0.59) | GRM5MAPTLMNAALDH1A1TP53 | |
| SCHEMBL8289183 | 0.82 | GRM5 (0.72) | GRM5MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2482825 | 0.81 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL14133258 | 0.80 | PTPN1 (0.83) | GRM5MAPTLMNAALDH1A1NTRK1 | |
| SCHEMBL15070769 | 0.77 | MAPT (0.75) | GRM5MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14133182 | 0.77 | MAPT (0.79) | GRM5MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14132521 | 0.76 | MAPT (0.77) | GRM5MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5924123 | 0.76 | GRM5 (1.00) | GRM5MAPTLMNAALDH1A1NTRK1 | |
| SCHEMBL11471937 | 0.76 | GRM5 (0.64) | GRM5MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | GRM5 2120/4885MAPT 1671/4885LMNA 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.